Immuneering (IMRX) Other Working Capital Changes (2020 - 2026)
Immuneering (IMRX) posted quarterly Other Working Capital Changes of -$94221.0 for Q1 2026, down 17.57% year-over-year from -$114307.0 in Q1 2025, and down 2.52% quarter-over-quarter from -$91904.0 in Q4 2025.
Immuneering (IMRX) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Immuneering's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$94221.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 17.57% year-over-year to -$94221.0; the TTM figure through Mar 2026 stood at -$352514.0 (down 18.08% YoY), while the FY2025 annual figure was -$338432.0, down 12.77% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$94221.0, down from -$91904.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $1.4 million in Q2 2022, with the low at -$1.5 million in Q2 2025.
- The 5-year median for Other Working Capital Changes is $4083.0 (2022), against an average of -$13826.7.
- The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes soared 60.59% in 2022, then tumbled 724.65% in 2023.
- Immuneering's Other Working Capital Changes stood at -$9664.0 in 2022, then tumbled by 724.65% to -$79694.0 in 2023, then grew by 1.91% to -$78168.0 in 2024, then retreated by 17.57% to -$91904.0 in 2025, then decreased by 2.52% to -$94221.0 in 2026.
- Business Quant data shows IMRX's Other Working Capital Changes at -$94221.0 in Q1 2026, -$91904.0 in Q4 2025, and -$84230.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96,597.00 |
| Jun 30, 2026 | -96,597.00 |
| Jun 30, 2026 | -96,597.00 |
| Mar 31, 2026 | -94,221.00 |
| Mar 31, 2026 | -94,221.00 |
| Mar 31, 2026 | -94,221.00 |
| Dec 31, 2025 | -91,904.00 |
| Dec 31, 2025 | -91,904.00 |
| Dec 31, 2025 | -91,904.00 |
| Sep 30, 2025 | -84,230.00 |
| Sep 30, 2025 | -84,230.00 |
| Sep 30, 2025 | -84,230.00 |
| Jun 30, 2025 | -82,159.00 |
| Jun 30, 2025 | -82,159.00 |
| Jun 30, 2025 | -82,159.00 |
| Mar 31, 2025 | -80,139.00 |
| Mar 31, 2025 | -80,139.00 |
| Mar 31, 2025 | -80,139.00 |
| Dec 31, 2024 | -78,168.00 |
| Dec 31, 2024 | -78,168.00 |